Keisha Hearn

621 total citations
4 papers, 148 citations indexed

About

Keisha Hearn is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Keisha Hearn has authored 4 papers receiving a total of 148 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 2 papers in Pulmonary and Respiratory Medicine and 1 paper in Oncology. Recurrent topics in Keisha Hearn's work include ATP Synthase and ATPases Research (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Cancer therapeutics and mechanisms (1 paper). Keisha Hearn is often cited by papers focused on ATP Synthase and ATPases Research (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Cancer therapeutics and mechanisms (1 paper). Keisha Hearn collaborates with scholars based in United Kingdom and United States. Keisha Hearn's co-authors include Neil T. Thompson, Nicola G. Wallis, Tomoko Smyth, John F. Lyons, Kim H.T. Paraiso, Joanne M. Munck, Mohammad Azab, Keiran S.M. Smalley, Vernon K. Sondak and H. Eirik Haarberg and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and British Journal of Cancer.

In The Last Decade

Keisha Hearn

4 papers receiving 143 citations

Peers

Countries citing papers authored by Keisha Hearn

Since Specialization

Citations

This map shows the geographic impact of Keisha Hearn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keisha Hearn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keisha Hearn more than expected).

Fields of papers citing papers by Keisha Hearn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keisha Hearn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keisha Hearn. The network helps show where Keisha Hearn may publish in the future.

Co-authorship network of co-authors of Keisha Hearn

This figure shows the co-authorship network connecting the top 25 collaborators of Keisha Hearn. A scholar is included among the top collaborators of Keisha Hearn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keisha Hearn. Keisha Hearn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

4 of 4 papers shown

#	Work	Indexed citations
1	Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP) 2017 ·Journal of Medicinal Chemistry ·Emiliano Tamanini, Ildiko M. Buck, Gianni Chessari, Elisabetta Chiarparin, James E. H. Day, Martyn Frederickson, Charlotte Griffiths-Jones, Keisha Hearn, Tom D. Heightman, Aman Iqbal, Christopher N. Johnson, Edward J. Lewis, Vanessa Martins, Torren M. Peakman, Michael Reader, Sharna J. Rich, George A. Ward, Pamela A. Williams, Nicola E. Wilsher	57
2	Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib 2016 ·British Journal of Cancer ·Aurélie Courtin, Tomoko Smyth, Keisha Hearn, Harpreet K. Saini, Neil T. Thompson, John F. Lyons, Nicola G. Wallis	23
3	Abstract 2688: The HSP90 inhibitor, onalespib (AT13387), delays the emergence of resistance to erlotinib in an EGFR-driven xenograft model 2015 ·Cancer Research ·Aurélie Courtin, Tomoko Smyth, Keisha Hearn, John C. Lyons, Neil T. Thompson, Nicola G. Wallis	2
4	Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models 2014 ·Molecular Cancer Therapeutics ·Tomoko Smyth, Kim H.T. Paraiso, Keisha Hearn, (unknown), Joanne M. Munck, H. Eirik Haarberg, Vernon K. Sondak, Neil T. Thompson, Mohammad Azab, John F. Lyons, Keiran S.M. Smalley, Nicola G. Wallis	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact